Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study.

Content Provider	Europe PMC
Author	Rozzini, Luca Chilovi, Barbara Vicini Bertoletti, Erik Conti, Marta Delrio, Ilenia Trabucchi, Marco Padovani, Alessandro
Abstract	Cholinesterase inhibitors (ChEIs) are effective in improving cognition and behavior in patients affected by Alzheimer’s disease (AD) as well as by Lewy bodies dementia (DLB). The authors compared the effect of rivastigmine in the treatment of cognitive impairment and behavioral and psychological symptoms of dementia (BPSD) in 30 AD and in 30 DLB patients. At baseline, DLB compared to AD patients showed a greater number of extrapyramidal symptoms (P < .005) and were similar regarding cognitive symptoms and BPSD. After treatment, both groups showed a comparable cognitive and psycho-behavioral improvement. A significant difference between AD and DLB patients was found for hallucinations (P < .002). Rivastigmine produces comparable cognitive benefits in patients with DLB and AD and also a significant improvement of behavioral disorders. These findings support the view that ChEIs should be considered a first-line treatment of the cognitive and psycho-behavioral symptoms of both AD and DLB.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC10697208&blobtype=pdf
ISSN	15333175
Volume Number	22
DOI	10.1177/1533317506297517
PubMed Central reference number	PMC10697208
Issue Number	1
PubMed reference number	17534001
Journal	American Journal of Alzheimer's Disease and Other Dementias [Am J Alzheimers Dis Other Demen]
e-ISSN	19382731
Language	English
Publisher	SAGE Publications
Publisher Date	2007-02-01
Publisher Place	Sage CA: Thousand Oaks, CA
Access Restriction	Open
Subject Keyword	Alzheimer’s disease dementia with Lewy bodies cholinesterase inhibitors BPSD
Content Type	Text
Resource Type	Article
Subject	Neuroscience Clinical Psychology Psychiatry and Mental Health Geriatrics and Gerontology